Literature DB >> 30875426

Chronic Treatment With Acetylcholinesterase Inhibitors Attenuates Vascular Dysfunction in Spontaneously Hypertensive Rats.

Renata M Lataro1, Marcondes A B Silva2, Fabiola L Mestriner2, Stefany B A Cau2, Rita C A Tostes2, Helio C Salgado3.   

Abstract

BACKGROUND: Acetylcholinesterase inhibition prevents autonomic imbalance, reduces inflammation, and attenuates the development of hypertension. Considering that vascular dysfunction is a crucial feature of arterial hypertension, we investigated the effects of chronic administration of acetylcholinesterase inhibitors-pyridostigmine or donepezil-on vascular reactivity of spontaneously hypertensive rats (SHR).
METHODS: Endothelium-dependent relaxant responses to acetylcholine (ACh) and contractile responses induced by electric field stimulation (EFS) and alpha-adrenergic agonist were studied in mesenteric resistance arteries from SHR and Wistar Kyoto rats. SHR were treated for 16 weeks with vehicle, pyridostigmine (1.5 mg/kg/day) or donepezil (1.4 mg/kg/day).
RESULTS: Pyridostigmine and donepezil decreased the vasoconstrictor responses to EFS, which were increased in vehicle-treated SHR. Acetylcholinesterase inhibition increased the modulatory effects of nitric oxide (NO) on SHR vascular reactivity, that is, N(ω)-nitro-(L)-arginine methyl ester (L-NAME) increased EFS-induced contractions and reduced ACh-induced relaxation, with more significant effects in pyridostigmine- and donepezil-treated SHR. The acetylcholinesterase inhibitors also decreased vascular reactive oxygen species levels.
CONCLUSIONS: This study demonstrates for the first time that long-term administration of acetylcholinesterase inhibitors, pyridostigmine or donepezil, attenuates vascular reactivity dysfunction in SHR by decreasing reactive oxygen species generation and increasing NO bioavailability; possibly via increased endothelial NO synthase activity, and inhibition of NADPH oxidase activity. © American Journal of Hypertension, Ltd 2019. All rights reserved. For Permissions, please email: journals.permissions@oup.com.

Entities:  

Keywords:  Acetylcholinesterase inhibition; blood pressure; donepezil; hypertension; parasympathetic activation; pyridostigmine

Year:  2019        PMID: 30875426     DOI: 10.1093/ajh/hpz036

Source DB:  PubMed          Journal:  Am J Hypertens        ISSN: 0895-7061            Impact factor:   2.689


  4 in total

1.  Quantification of dynamic cerebral autoregulation and CO2 dynamic vasomotor reactivity impairment in essential hypertension.

Authors:  Vasilis Z Marmarelis; Dae C Shin; Mareike Oesterreich; Martin Mueller
Journal:  J Appl Physiol (1985)       Date:  2020-01-09

2.  Cholinergic stimulation with pyridostigmine modulates a heart-spleen axis after acute myocardial infarction in spontaneous hypertensive rats.

Authors:  Robson Luiz Bandoni; Pamela Nithzi Bricher Choque; Humberto Dellê; Tercio Lemos de Moraes; Maria Helena Mattos Porter; Bruno Durante da Silva; Gizele Alves Neves; Maria-Claudia Irigoyen; Kátia De Angelis; Valentin A Pavlov; Luis Ulloa; Fernanda Marciano Consolim-Colombo
Journal:  Sci Rep       Date:  2021-05-05       Impact factor: 4.379

3.  Preclinical Evaluation of the Antihypertensive Effect of an Aqueous Extract of Anogeissus leiocarpa (DC) Guill et Perr. Bark of Trunk in L-NAME-Induced Hypertensive Rat.

Authors:  Lazare Belemnaba; Mathieu Nitiéma; Sylvain Ilboudo; Gueswindé Geoffroy Ouédraogo; Noufou Ouédraogo; Mohamed Bonewendé Belemlilga; Souleymane Compaoré; Salfo Ouédraogo; Sylvin Ouédraogo
Journal:  J Exp Pharmacol       Date:  2021-08-07

4.  Donepezil improves vascular function in a mouse model of Alzheimer's disease.

Authors:  Carolina Pellegrini; Vanessa D'Antongiovanni; Matteo Fornai; Emiliano Duranti; Filippo Baldacci; Nunzia Bernardini; Stefano Taddei; Agostino Virdis; Corrado Blandizzi; Stefano Masi; Luca Antonioli
Journal:  Pharmacol Res Perspect       Date:  2021-12
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.